Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2291)	2/26/2008 2:45:00 PM
From: Jibacoa	Respond to of 3722

PRAN opened with an UG & is is still up 42% on volume of 1,520,082 about 50x its ADV. bigcharts.marketwatch.com It announced today that PBT2 has demonstrated safety and tolerability and reduced Abeta 42, in a PIIa in patients with early AD. It also improved executive function performance in select cognitive tests. PBT2 had previously shown, in transgenic mouse,that it could inhibit the toxic oligomers of Abeta that is thought to cause the functional damage in AD. In this PIIa in 78 patients in Sweden and Australia were randomized to receive either a placebo, PBT2 50mg or PBT2 250mg 1x daily for 12 weeks & the data demonstrated that the safety and tolerability profile of PBT2 at both doses was similar to that of placebo. It seems that the stock should have no problem in closing above its Jan 14 H of $4.90 The Apr 2004 H was $10.50 & the Sep 2002 H at the time of its IPO was $12.80 <g> bigcharts.marketwatch.com Bernard